Atlas market file · Equity · United States
Nkarta, Inc.NKTX
- Last close
- 2.29
- Change
- +4.09%
- 96-bar range
- 1.96 – 3.72
- As of
- 6 Aug 2026
Nkarta, Inc. is a pharmaceutical preparations issuer listed as NKTX on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
NKTX
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-56.95% over the window).
Source rail: Yahoo Finance chart API (NKTX). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for NKTX. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
NKTX public profile
Pharmaceutical preparations issuer. Nkarta, Inc. is connected to current market context, cited company sources and its retained research file.
Nkarta, Inc. trades as NKTX on NASDAQ. Nkarta, Inc. (NKTX) has a latest verified close of 2.29, up 4.09%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files NKTX under USA Stocks for browsing.
What changed for Nkarta, Inc. today
Nkarta, Inc. (NKTX) reported a net loss of $27.8M in Q1 2026, with cash and short-term investments totaling $230.5M, according to its SEC filing. The clinical-stage biotech, which has yet to bring a product to market, spent $25.0M on R&D during the quarter, underscoring its reliance on capital raises to sustain operations.
The company’s pipeline includes NKX019, an off-the-shelf NK cell therapy targeting CD19, and the Ntrust-1 Phase 1 trial for lupus nephritis, which began dosing in 2026. Despite this progress, Nkarta’s financials reveal a diluted EPS of -$0.37 and a 74.3M share count, raising questions about dilution risks as it pursues clinical milestones.
Recent SEC filings highlight an IRS audit of the company’s 2023 tax return and insider share sales in June 2026. These developments add layers of uncertainty to a story already defined by long timelines and high burn rates. Nkarta’s ability to advance trials without a near-term revenue source remains a key tension point.
The stock’s market dynamics reflect its speculative nature: no revenue, heavy R&D, and a liquidity position that buys time but not infinite runway. Investors are left balancing the promise of NK cell therapy against the harsh math of cash outflows and regulatory timelines.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
NKTX technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on NKTX
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep NKTX research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
NKTX FAQ
What is Nkarta, Inc. (NKTX)?Nkarta, Inc. (NKTX) has a latest verified close of 2.29, up 4.09%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
Nkarta, Inc. (NKTX) has a latest verified close of 2.29, up 4.09%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for NKTX?Nkarta, Inc. (NKTX) has a latest verified close of 2.29, up 4.09%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the...
Nkarta, Inc. (NKTX) has a latest verified close of 2.29, up 4.09%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files NKTX under USA Stocks for browsing.
How often is the NKTX page updated?The NKTX public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The NKTX public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for NKTX?The NKTX file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:NKTX. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The NKTX file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:NKTX. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on NKTX?Yes. The workstation can open NKTX, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open NKTX, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this NKTX page investment advice?No. The NKTX page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The NKTX page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →